DK2279206T3 - METHOD FOR PREVENTING THE DEVELOPMENT of rheumatoid arthritis in individuals with undifferentiated ARTHRITIS - Google Patents

METHOD FOR PREVENTING THE DEVELOPMENT of rheumatoid arthritis in individuals with undifferentiated ARTHRITIS Download PDF

Info

Publication number
DK2279206T3
DK2279206T3 DK09743410.4T DK09743410T DK2279206T3 DK 2279206 T3 DK2279206 T3 DK 2279206T3 DK 09743410 T DK09743410 T DK 09743410T DK 2279206 T3 DK2279206 T3 DK 2279206T3
Authority
DK
Denmark
Prior art keywords
subjects
ctla4lg
molecule
study
ctla4
Prior art date
Application number
DK09743410.4T
Other languages
Danish (da)
English (en)
Inventor
Jean-Claude Becker
Michael Corbo
George Vratsanos
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41264941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2279206(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK2279206T3 publication Critical patent/DK2279206T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DK09743410.4T 2008-05-05 2009-05-05 METHOD FOR PREVENTING THE DEVELOPMENT of rheumatoid arthritis in individuals with undifferentiated ARTHRITIS DK2279206T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5033608P 2008-05-05 2008-05-05
US12/387,359 US7915222B2 (en) 2008-05-05 2009-05-01 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
PCT/US2009/042761 WO2009137424A1 (en) 2008-05-05 2009-05-05 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Publications (1)

Publication Number Publication Date
DK2279206T3 true DK2279206T3 (en) 2015-07-27

Family

ID=41264941

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09743410.4T DK2279206T3 (en) 2008-05-05 2009-05-05 METHOD FOR PREVENTING THE DEVELOPMENT of rheumatoid arthritis in individuals with undifferentiated ARTHRITIS

Country Status (25)

Country Link
US (3) US7915222B2 (cg-RX-API-DMAC7.html)
EP (2) EP2279206B1 (cg-RX-API-DMAC7.html)
JP (1) JP2011522795A (cg-RX-API-DMAC7.html)
KR (1) KR20110014180A (cg-RX-API-DMAC7.html)
CN (1) CN102037010A (cg-RX-API-DMAC7.html)
AR (1) AR071672A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009244448B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0912249A2 (cg-RX-API-DMAC7.html)
CA (1) CA2723698C (cg-RX-API-DMAC7.html)
CL (1) CL2009001082A1 (cg-RX-API-DMAC7.html)
DK (1) DK2279206T3 (cg-RX-API-DMAC7.html)
EA (1) EA201001749A1 (cg-RX-API-DMAC7.html)
ES (1) ES2539840T3 (cg-RX-API-DMAC7.html)
HK (1) HK1208230A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20150552T1 (cg-RX-API-DMAC7.html)
HU (1) HUE025256T2 (cg-RX-API-DMAC7.html)
IL (1) IL208691A (cg-RX-API-DMAC7.html)
MX (1) MX2010011503A (cg-RX-API-DMAC7.html)
NZ (1) NZ589020A (cg-RX-API-DMAC7.html)
PL (1) PL2279206T3 (cg-RX-API-DMAC7.html)
PT (1) PT2279206E (cg-RX-API-DMAC7.html)
SI (1) SI2279206T1 (cg-RX-API-DMAC7.html)
TW (2) TWI454278B (cg-RX-API-DMAC7.html)
WO (1) WO2009137424A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007914B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
WO2013053767A1 (en) * 2011-10-10 2013-04-18 Medimmune Limited Treatment for rheumatoid arthritis
US20140006055A1 (en) * 2012-06-27 2014-01-02 Iagnosis, Inc. Integrated Medical Evaluation and Record Keeping System
US20150232558A1 (en) * 2012-10-30 2015-08-20 Emory University Stimulating bone formation by inhibition of cd28 co-stimulation
WO2014151230A2 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
JP2017513903A (ja) * 2014-04-25 2017-06-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 早期ｒａを有する対象において薬剤フリー寛解を達成するためのｃｔｌａ４化合物の使用
SI3283508T1 (sl) 2015-04-17 2021-09-30 Alpine Immune Sciences, Inc. Imunomodulirajoči proteini z nastavljivimi afinitetami
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
CN110148465B (zh) * 2019-05-10 2023-07-04 中山大学孙逸仙纪念医院 一种用于分析类风湿性关节炎的系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070776B1 (en) 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US5521288A (en) 1990-03-26 1996-05-28 Bristol-Myers Squibb Company CD28IG fusion protein
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
CA2110518C (en) 1991-06-27 2007-05-22 Peter S. Linsley Ctla4 receptor, fusion proteins containing it and uses thereof
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
EP0683793A4 (en) * 1993-01-21 1997-04-09 Univ Georgia Res Found VACCINES AND METHODS FOR THE PREVENTION AND TREATMENT OF FETUS-BASED TOXICOSIS IN HERBIVORES.
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
WO1997034633A1 (en) 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US20030219863A1 (en) 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
IL152316A0 (en) 2000-06-09 2003-05-29 Bristol Myers Squibb Co Pharmaceutical compositions and kits for treating transplant rejection
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
SI1372696T1 (sl) * 2000-07-03 2008-12-31 Bristol Myers Squibb Co Metoda za zdravljenje revmatskih bolezni z uporabo topne molekule ctla4
HUP0303930A3 (en) 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
CN100402660C (zh) 2002-12-23 2008-07-16 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高
CN101857851A (zh) 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
JP2007501243A (ja) 2003-08-04 2007-01-25 ブリストル−マイヤーズ　スクイブ　カンパニー 可溶性ｃｔｌａ４分子を用いる心臓血管疾患の治療方法
US10092429B2 (en) * 2005-08-22 2018-10-09 Incept, Llc Flared stents and apparatus and methods for delivering them
WO2007000020A1 (en) 2005-06-29 2007-01-04 Compumedics Limited Sensor assembly with conductive bridge
PT1962886E (pt) 2005-12-20 2014-01-07 Bristol Myers Squibb Co Formulações de proteína estáveis
SI1969007T1 (sl) 2005-12-20 2014-03-31 Bristol-Myers Squibb Company Sestavki in postopki za izdelavo sestavka
US7528111B2 (en) 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Also Published As

Publication number Publication date
IL208691A0 (en) 2010-12-30
KR20110014180A (ko) 2011-02-10
TW201444575A (zh) 2014-12-01
EP2279206B1 (en) 2015-04-22
MX2010011503A (es) 2010-11-09
ES2539840T3 (es) 2015-07-06
PT2279206E (pt) 2015-07-27
US20090280119A1 (en) 2009-11-12
US7915222B2 (en) 2011-03-29
AU2009244448B2 (en) 2014-07-31
US8435952B2 (en) 2013-05-07
HK1148291A1 (en) 2011-09-02
EP2279206A4 (en) 2011-05-25
NZ589020A (en) 2012-05-25
EP2891665A1 (en) 2015-07-08
CL2009001082A1 (es) 2010-02-12
IL208691A (en) 2015-01-29
EA201001749A1 (ru) 2011-06-30
ZA201007914B (en) 2011-07-27
TW200948381A (en) 2009-12-01
WO2009137424A1 (en) 2009-11-12
CN102037010A (zh) 2011-04-27
US9012408B2 (en) 2015-04-21
JP2011522795A (ja) 2011-08-04
US20130195865A1 (en) 2013-08-01
US20110142835A1 (en) 2011-06-16
CA2723698C (en) 2018-03-06
BRPI0912249A2 (pt) 2015-10-20
EP2279206A1 (en) 2011-02-02
SI2279206T1 (sl) 2015-08-31
CA2723698A1 (en) 2009-11-12
AR071672A1 (es) 2010-07-07
HUE025256T2 (en) 2016-02-29
TWI454278B (zh) 2014-10-01
PL2279206T3 (pl) 2015-09-30
HK1208230A1 (en) 2016-02-26
AU2009244448A1 (en) 2009-11-12
HRP20150552T1 (hr) 2015-06-19

Similar Documents

Publication Publication Date Title
DK2279206T3 (en) METHOD FOR PREVENTING THE DEVELOPMENT of rheumatoid arthritis in individuals with undifferentiated ARTHRITIS
US10052360B2 (en) Methods for treating dermatomyositis or polymyositis by administering a soluble CTLA4 molecule
US20200069772A1 (en) Methods of treating early rheumatoid arthritis
WO2003088991A9 (en) Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
AU2014213571B2 (en) Method of preventing the development of rheumatoid arthritis in subjects with un-differentiated arthritis
HK1148291B (en) Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
WO2014151230A2 (en) Method of treating granulomatosis with polyangiitis